Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07549399CT.gov SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC | — | Not Yet Recruiting | — | — | — |
NCT06908031CT.gov SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer | — | Recruiting | — | — | — |
NCT06321081CT.gov ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | — | Recruiting | — | — | — |
NCT06199232CT.gov Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment | — | Active Not Recruiting | — | — | — |
NCT05733611CT.gov RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | — | Terminated | — | — | — |
NCT04659382CT.gov Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04527068CT.gov QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marinesco-Sjogren Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B · 61 |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Nivolumab | Pfizer | P2 | B |
| Ipilimumab | Pfizer | P2 | B |
| Binimetinib | Pfizer | P2 | B |
| Celecoxib | Sun Yat-sen University | P2 | CCC |
| Toripalimab | Sun Yat-sen University | P2 | CCC |
| Regorafenib | Sun Yat-sen University | P2 | CCC |
+12 more in the Marinesco-Sjogren Syndrome cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Marinesco-Sjogren Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-marinesco-sjogren-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →